The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5886-5893

  Graham Robinett, R ^a   Freemerman, Alex J ^b   Skinner, Michael A ^b   Shewchuk, Lisa ^a   Lackey, Karen ^a  

^a GLAXOSMITHKLINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

4 Anilinoquinolines; c src; Kinase inhibitors; RET

Indexed keywords

4 (3 HYDROXYANILINO)QUINOLINE DERIVATIVE; 4 ANILINOQUINOLINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLINE DERIVATIVE; RET KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; ENZYME INHIBITION; EVALUATION RESEARCH; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; SUBSTITUTION REACTION; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

BINDING SITES; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; QUINOLINES;

EID: 34548864404     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.07.104     Document Type: Article

References (33)

1. Golden J.P., DeMaro J.A., Osborne P.A., Milbrandt J., and Johnson Jr. E.M. Exp. Neurol. 158 (1999) 504
2. Arighi E., Borrello M.G., and Sariola H. Cytokine Growth F. R. 16 (2005) 441
3. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Conte-Devolx B., Falchetti A., Gheri R.G., Libroia A., Lips C.J., Lombardi G., Mannelli M., Pacini F., Ponder B.A., Raue F., Skogseid B., Tamburrano G., Thakker R.V., Thompson N.W., Tomassetti P., Tonelli F., Wells Jr. S.A., and Marx S.J. J. Clin. Endocrin. Metab. 86 (2001) 5658
4. Milano A., Chiofalo M.G., Basile M., Salzano de Luna A., Pezzullo L., and Caponigro F. Anti-Cancer Drug Des. 17 (2006) 869
5. Carniti C., Perego C., Mondellini P., Pierotti M.A., and Bongarzone I. Cancer Res. 63 (2003) 2234
6. Carlomagno F., Vitagliano D., Guida T., Basolo F., Castellone M.D., Melillo R.M., Fusco A., and Santoro M. J. Clin. Endocrin. Metab. 88 (2003) 1897
7. Sathornsumetee S., and Rich J.N. Drug Discov. Today 42 (2006) 657
8. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., and Santoro M. J. Natl. Cancer Inst. 98 (2006) 326
9. Carlomagno F., Vitagliano D., Guida T., Napolitano M., Vecchio G., Fusco A., Gazit A., Levitzki A., and Santoro M. Cancer Res. 62 (2002) 1077
10. Robert C., Soria J.-C., Spatz A., Le Cesne A., Malka D., Pautier P., Wechsler J., Lhomme C., Escudier B., Boige V., Armand J.-P., and Le Chevalier T. Lancet Oncol. 6 (2005) 491
11. Seijas J.A., Vazquez-Tato M.P., and Carballido-Reboredo R. J. Org. Chem. 70 (2005) 2855
12. Bramson H.N., Corona J., Davis S.T., Dickerson S.H., Edelstein M., Frye S.V., Gampe Jr. R.T., Harris P.A., Hassell A., Holmes W.D., Hunter R.N., Lackey K.E., Lovejoy B., Luzzio M.J., Montana V., Rocque W.J., Rusnak D., Shewchuk L., Veal J.M., Walker D.H., and Kuyper L.F. J. Med. Chem. 44 (2001) 4339
13. Cheung M., Hunter III R.N., Peel M.R., and Lackey K.E. Heterocycles 55 (2001) 1583
14. Mologni L., Sala E., Cazzaniga S., Rostagno R., Kuoni T., Puttini M., Bain J., Cleris L., Redaelli S., Riva B., Formelli F., Scapozza L., and Gambacorti-Passerini C. J. Mol. Endocrinol. 37 (2006) 199
15. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., and Wood E.R. J. Biol. Chem. 277 (2002) 1576
16. Synthesis is included in this paper, and in a pending patent application publication.
17. Lackey K., Cory M., Davis R., Frye S.V., Harris P.A., Hunter R.N., Jung D.K., McDonald O.B., McNutt R.W., Peel M.R., Rutkowske R.D., Veal J.M., and Wood E.R. Bioorg. Med. Chem. Lett. 10 (2000) 223
18. Hudson, A. T.; Vile, S.; Barraclough, P.; Franzmann, K. W.; McKeown, S. C.; Page, M. J. PCT Int. Appl. 1996, WO9609294 A1.
19. 4. Each phosphocellulose filter was transferred into a separate scintillation vial, 1 mL cytoscint fluid was added, and the sample counted on a Packard 1900TR liquid scintillation analyzer for 1 min.
20. Graves P.R., Kwiek J.J., Fadden P., Ray R., Hardeman K., Coley A.M., Foley M., and Haystead T.A. J. Mol. Pharm. 62 (2002) 1364
21. Roche A.J., and Canturk B. Org. Biomol. Chem. 3 (2005) 515
22. De D., Krogstad F.M., Byers L.D., and Krogstad D.J. J. Med. Chem. 41 (1998) 4918
23. De D., Byers L.D., and Krogstad D.J. J. Heterocycl. Commun. 34 (1997) 315
24. Vippagunta S.R., Dorn A., Matile H., Bhattacharjee A.K., Karle J.M., Ellis W.Y., Ridley R.G., and Vennerstrom J.L. J. Med. Chem. 42 (1999) 4630
25. Wunberg T., Hendrix M., Hillisch A., Lobell M., Meier H., Schmeck C., Wild H., and Hinzen B. Drug Discov. Today 11 (2006) 175
26. Lackey K.E. Curr. Top. Med. Chem. 6 (2006) 435
27. Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., Santoro M., Ibanez C.F., and McDonald N.Q. J. Biol. Chem. 281 (2006) 33577
28. Shewchuk L., Hassell A., Wisely B., Rocque W., Holmes W., Veal J., and Kuyper L.F. J. Med. Chem. 43 (2000) 133
29. The extracellular region and transmembrane domain of the human EGFR (amino acids 1-668) were combined with the intracellular region of RET (RET9 [amino acids 658-1072]). The human neuroblastoma cell line, SK-N-MC, was utilized to establish cell lines expressing the EGFR/RET construct and an empty vector control. The assay was performed by pre-incubating EGFR/RET-expressing cells for 30 min in serum-free MEM with increasing concentrations of GW569998X, GW585550A, or GW559768X and then activating RET by the addition of human epidermal growth factor (EGF) (100 ng/mL) for 10 min. Experimental incubations were terminated by collecting and directly lysing cells in 1× Laemmli (1% SDS, 10% glycerol, 100 mM dithiothreitol, and 50 mM Tris, pH 6.8) for Western blots. Western blots were sequentially probed for phospho-RET (Tyr-1062-R), RET9 (C-19) (Santa Cruz Biotechnology, Santa Cruz, CA), and actin (MAB1501) (Chemicon International, Temecula, CA). Yeatman, T. J. Nat. Rev. Cancer 2004, 4, 470-480.
30. Yeatman T.J. Nat. Rev. Cancer 4 (2004) 470
31. Ptasznik A., Nakata Y., Kalota A., Emerson S.G., and Gewirtz A.M. Nat. Med. 10 (2004) 1187
32. Teicher B.A. Cancer Ther. (2005) 221
33. More indepth biological evaluation of these ret kinase inhibitors is included in a submitted manuscript by Michael A. Skinner, Jeffrey F. Moley, Karen E. Lackey, and Alex J. Freemerman, titled RET oncogene activation raises the apoptotic threshold in SK-N-MC cells.